ArticlePhotochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology2025
Effects of hypoxic and photobiomodulation preconditioning on mesenchymal stem cell-derived exosomes: an in vitro study with an osteogenic potential approach.
Article in Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FeBioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Mesenchymal stem cell-derived exosomes (MSC-Exos) have emerged as promising therapeutic agents for bone regeneration due to their regenerative and immunomodulatory properties. This study investigates the effects of hypoxic and Photobiomodulation (PBM) preconditioning on the characteristics and functional properties of exosomes derived from human adipose-derived mesenchymal stem cells (hAdMSCs), with a focus on bone regeneration. hAdMSCs were characterized by their spindle-shaped morphology and high expression of mesenchymal markers (CD73: 99.6%, CD105: 99.9%) and minimal expression of hematopoietic and endothelial markers (CD45: 0.2%, CD31: 2.25%). Exosomes were isolated from hAdMSCs cultured under normal (N-EX), hypoxic (H-EX), PBM (PBM-EX), and combined PBM + hypoxia (PBM + H-EX) conditions. Exosomal markers (CD9, CD63, and CD81) and size distribution (72.2-88.4 nm) confirmed successful isolation, with no significant differences in size between different groups. Functional assays revealed that a 200 µg exosome dose significantly enhanced cell proliferation and metabolic activity (p < 0.0001). Exosome-treated groups exhibited significantly enhanced cell viability, maintained stable glucose uptake, and accelerated migration compared to control groups. Notably, the PBM-EX group demonstrated the most remarkable outcomes, achieving complete scratch closure within just 20 h. Osteogenic differentiation potential, assessed via alkaline phosphatase (ALP) activity and Alizarin Red S (ARS) staining, revealed that the PBM-EX group exhibited the highest ALP activity and mineralization levels (p < 0.0001), followed by the PBM + H-EX, H-EX, and N-EX groups. These findings suggest that PBM preconditioning enhances the regenerative potential of hAdMSC-derived exosomes, making it a promising strategy for bone tissue engineering and regenerative medicine applications.
Indexed as
Identifiers
41239027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.